Sawgrass Asset Management LLC bought a new stake in ANI Pharmaceuticals Inc (NASDAQ:ANIP) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 6,295 shares of the specialty pharmaceutical company’s stock, valued at approximately $517,000. Sawgrass Asset Management LLC owned 0.05% of ANI Pharmaceuticals at the end of the most recent reporting period.
Other institutional investors have also made changes to their positions in the company. Dimensional Fund Advisors LP increased its stake in ANI Pharmaceuticals by 1.3% in the 4th quarter. Dimensional Fund Advisors LP now owns 518,427 shares of the specialty pharmaceutical company’s stock valued at $23,339,000 after buying an additional 6,546 shares during the period. First Manhattan Co. increased its stake in ANI Pharmaceuticals by 2.2% in the 1st quarter. First Manhattan Co. now owns 240,166 shares of the specialty pharmaceutical company’s stock valued at $16,941,000 after buying an additional 5,171 shares during the period. Phocas Financial Corp. increased its stake in ANI Pharmaceuticals by 8.9% in the 1st quarter. Phocas Financial Corp. now owns 140,977 shares of the specialty pharmaceutical company’s stock valued at $9,945,000 after buying an additional 11,501 shares during the period. Geode Capital Management LLC increased its stake in ANI Pharmaceuticals by 3.0% in the 4th quarter. Geode Capital Management LLC now owns 97,459 shares of the specialty pharmaceutical company’s stock valued at $4,387,000 after buying an additional 2,827 shares during the period. Finally, Global Alpha Capital Management Ltd. acquired a new position in ANI Pharmaceuticals in the 1st quarter valued at $6,808,000. 64.04% of the stock is currently owned by institutional investors and hedge funds.
In related news, SVP Robert W. Schrepfer sold 2,409 shares of the business’s stock in a transaction dated Monday, May 13th. The shares were sold at an average price of $71.13, for a total value of $171,352.17. Following the sale, the senior vice president now directly owns 55,927 shares in the company, valued at approximately $3,978,087.51. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Thomas Haughey acquired 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, May 15th. The stock was acquired at an average price of $69.30 per share, for a total transaction of $173,250.00. Following the completion of the transaction, the director now directly owns 6,291 shares in the company, valued at $435,966.30. The disclosure for this purchase can be found here. Insiders have sold a total of 50,911 shares of company stock worth $3,585,114 over the last 90 days. Insiders own 24.70% of the company’s stock.
Shares of NASDAQ ANIP traded down $0.15 during trading on Friday, hitting $84.33. 81,272 shares of the company were exchanged, compared to its average volume of 120,687. The stock has a market cap of $1.02 billion, a P/E ratio of 18.29 and a beta of 2.17. ANI Pharmaceuticals Inc has a 1 year low of $36.92 and a 1 year high of $86.96. The stock has a fifty day moving average price of $80.46. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.67 and a current ratio of 0.92.
ANI Pharmaceuticals (NASDAQ:ANIP) last issued its earnings results on Thursday, May 9th. The specialty pharmaceutical company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.05 by $0.25. The company had revenue of $52.90 million for the quarter, compared to analyst estimates of $50.57 million. ANI Pharmaceuticals had a net margin of 6.58% and a return on equity of 28.63%. The business’s revenue was up 13.8% on a year-over-year basis. During the same period in the previous year, the firm earned $1.32 EPS. As a group, sell-side analysts forecast that ANI Pharmaceuticals Inc will post 5.57 earnings per share for the current year.
Several equities analysts have issued reports on the stock. Raymond James cut shares of ANI Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and boosted their price objective for the company from $73.00 to $82.00 in a research note on Friday, May 10th. Canaccord Genuity restated a “buy” rating and set a $90.00 target price (up from $80.00) on shares of ANI Pharmaceuticals in a research report on Monday, May 13th. Zacks Investment Research lowered shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Wednesday. Cantor Fitzgerald restated a “buy” rating and set a $89.00 target price on shares of ANI Pharmaceuticals in a research report on Thursday, May 9th. Finally, BidaskClub upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Saturday, July 27th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $89.00.
ANI Pharmaceuticals Profile
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Featured Article: What is the role of the G-20?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.